Anti-Rheumatic Drugs - EMEA

EMEA

Revenue in the Anti-Rheumatic Drugs market is projected to reach US$6.28bn in 2024.
Revenue is expected to show an annual growth rate (CAGR 2024-2028) of 0.67%, resulting in a market volume of US$6.45bn by 2028.
In global comparison, most revenue will be generated in the United States (US$34,700.00m in 2024).

Key regions: Germany, United States, India, Japan, United Kingdom

Market

Region

Region comparison

Currency

Analyst Opinion

For the past years, Anti-Rheumatic Drugs has been the second largest section of the Pharmaceuticals market. While most patients are treated with painkillers and cheaper anti-inflammatory drugs, the overall revenue is dominated by expensive drugs that are taken by only a fraction of affected patients.

The market size is projected to decrease because of biosimilar competition for the market-leading product Humira by AbbVie. The drop in 2019 reflects the emergence of biosimilars outside of the U.S., while the decrease expected to occur towards the end of the time series is linked to the loss of exclusivity in the U.S.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.